Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
The purpose of this study was to perform population pharmacokinetic (PPK) analysis on carbamazepine and to determine the population model of clearance of this drug in terms of individual patient characteristics. A total of 107 steady-state serum concentrations from 97 adult and pediatric epileptic patients, collected during routine clinical care, were used for the analysis. To determine the influence of different covariates on the estimate of carbamazepine clearance we used the non-linear mixed effects modeling (NONMEM) software package with ADVAN1 subroutine. This is a one-compartment model with first-order elimination and without absorption. The typical mean value for carbamazepine clearance, estimated by the base model (without covariates), in our population was 3.43 l/h. The final results of our analysis show that carbamazepine clearance increased nonlinearly with total body weight and age, and linearly with concomitant administration of valproate. The magnitude of the effect of valproate was +0.874 l/h. The interindividual variability (coefficient of variation) for clearance and the residual variability (including intraindividual variability), described by an exponential error model, were 16.76% and 31.14%, respectively. The results of this PPK analysis were validated in a group of 16 epileptic patients and suggested good predictive performance of the final model. The derived model describes carbamazepine clearance in terms of characteristics of Serbian patients, using minimal data obtained from routine clinical care of epileptic patients. This is the basis for future pharmacokinetic studies on a specific epileptic population, which will lead to better overall management of epilepsy in Serbia.
Jankovic
Slobodan M
SM
Pharmacology Department, Medical Faculty, Clinical Center, University of Kragujevac, Kragujevac, Serbia.
Jovanovic
Dusan
D
Milovanovic
Jasmina R
JR
D000328:Adult; D000367:Age Factors; D000465:Algorithms; D000927:Anticonvulsants / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D002220:Carbamazepine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D016208:Databases, Factual / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D015203:Reproducibility of Results; D012189:Retrospective Studies; D055771:Serbia; D014635:Valproic Acid / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use
D000927:Anticonvulsants; D002220:Carbamazepine; D014635:Valproic Acid